Dr. Jimmie Harvey Jr., M.D. serves as Independent Director of the Company. Harvey has served as a member of the Board of Directors since December 2008. In 1984, Dr. Harvey founded Birmingham Hematology and Oncology Associates, L.L.C. (now Alabama Oncology, L.L.C.), a private medical company located in Birmingham, Alabama. Dr. Harvey has experience in clinical trial execution and management and has recently been a principal investigator in two trials, one investigating a novel monoclonal antibody and the other investigating a small molecule used to treat immunologic malignancies. Dr. Harvey holds a B.A. in chemistry from Emory University and received his M.D. from Emory University School of Medicine. Dr. Harvey completed his medical oncology training at the Vincent T. Lombardi Cancer Center at Georgetown University. Based on Dr. Harvey’s medical background, including his oncology expertise, the Board of Directors believes that Dr. Harvey has the appropriate set of skills to serve as a member of the Board in light of the Company’s business and structure.
As the Independent Director of Fortress Biotech Inc, the total compensation of Jimmie Harvey at Fortress Biotech Inc is $133,500. There are 10 executives at Fortress Biotech Inc getting paid more, with Robyn Hunter having the highest compensation of $1,798,070.
Jimmie Harvey is 68, he's been the Independent Director of Fortress Biotech Inc since 2008. There are 1 older and 9 younger executives at Fortress Biotech Inc. The oldest executive at Fortress Biotech Inc is Malcolm Hoenlein, 76, who is the Independent Director.
Jimmie's mailing address filed with the SEC is C/O FORTRESS BIOTECH, INC., 1111 KANE CONCOURSE SUITE 301, BAY HARBOR ISLANDS, FL, 33154.
Over the last 9 years, insiders at Fortress Biotech Inc have traded over $826,952 worth of Fortress Biotech Inc stock and bought 6,309,522 units worth $9,160,045 . The most active insiders traders include Lindsay A Md Rosenwald, Michael S Weiss és George Avgerinos. On average, Fortress Biotech Inc executives and independent directors trade stock every 77 days with the average trade being worth of $271,550. The most recent stock trade was executed by Lindsay A Md Rosenwald on 11 July 2024, trading 5,000 units of FBIO stock currently worth $37,400.
fortress biotech, inc. is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. fortress plans to develop and commercialize products that it acquires both directly as well as indirectly by establishing subsidiary companies, also known as fortress companies. the company will leverage its biopharmaceutical business expertise and drug development capabilities to help the fortress companies achieve their goals. additionally, the company will provide funding and management services to each of the fortress companies and from time to time the company and the fortress companies will seek licensing, partnerships, joint ventures, and/or public and private financings to accelerate and provide additional funding to support their research and development programs.
Fortress Biotech Inc executives and other stock owners filed with the SEC include: